Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

196.31 +1.13 (+0.58%)
Official Closing Price Updated: 7:00 PM EDT, Aug 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,820,805
Open 195.25
Bid (Size) 193.95 (1)
Ask (Size) 196.90 (8)
Prev. Close 195.18
Today's Range 194.17 - 196.50
52wk Range 135.85 - 198.30
Shares Outstanding N/A
Dividend Yield 3.02%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Stock Market Rally Mixed; Dow Jones Hits High While Nvidia Tumbles On Earnings: Weekly Review
The Dow Jones hit a new high while Nvidia led a Nasdaq retreat. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
2 Monster Stocks You Can Buy Right Now Before They Surge Even Higher
These businesses can stand the test of time in a diversified portfolio. 
Via The Motley Fool

Performance

YTD
+22.83%
+22.83%
1 Month
+5.93%
+5.93%
3 Month
+21.75%
+21.75%
6 Month
+9.73%
+9.73%
1 Year
+33.58%
+33.58%

More News

Read More
3 Rock-Solid Pharma Stocks to Buy Now and Hold Forever
Via The Motley Fool
2 Incredibly Cheap Healthcare Stocks to Buy Now
Via The Motley Fool
AbbVie Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
AbbVie Unusual Options Activity For August 26
Via Benzinga
Key Takeaways From AbbVie Analyst Ratings
Via Benzinga
Unpacking the Latest Options Trading Trends in AbbVie
Via Benzinga
Biotech And Life Science Sector Update Summer Of 2024
Via Talk Markets
Bull Market Buys: 3 Dividend Stocks to Own for the Long Run
Via The Motley Fool
As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors
Via Benzinga
Neurocrine Bio Dives As Schizophrenia Trial Results Lags Peers
Via Investor's Business Daily
3 Best Growth Stocks to Own for the Next 10 Years
Via MarketBeat
Topics Economy
Exposures Economy
$100 Invested In This Stock 10 Years Ago Would Be Worth $400 Today
Via Benzinga
Prediction: Eli Lilly's Latest Move Will Threaten AbbVie Stock
Via The Motley Fool
Regulators Expected To Approve Innovative Schizophrenia Treatment From Bristol Myers, Karuna
Via Benzinga
Donald Trump Owns These 21 Dividend Kings. Should You?
Via The Motley Fool
Topics Government
Exposures Political
3 Unstoppable Dividend Stocks to Buy Right Now
Via The Motley Fool
Novo Nordisk's Ozempic Might Be Among 2027 Medicare Price Negotiation Targets
Via Benzinga
How To Build A Dividend Growth Portfolio In An Overpriced Market
Via Talk Markets
Topics Stocks
Exposures US Equities
Biotech Bull Market: 3 Ways To Play It
Via Talk Markets
Topics Economy
Exposures Interest Rates
3 High-Yield Stocks to Buy Now That Have Increased Their Dividends for 25 Years or More
Via The Motley Fool
These 3 Healthcare Companies Had the Top-Selling Drugs Last Year
Via The Motley Fool
3 High-Yielding Dividend Growth Stocks That Retirees Can Rely On for Recurring Income
Via The Motley Fool
Lock in Gains: 3 Dividend Stocks Poised to Boost Payouts Soon
Via MarketBeat
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Economy
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.